Houston-based FlightAware, a software company that tracks flights, is growing. Cameron Casey/Pexels

FlightAware LLC's business success has, for the most part, flown under the radar in Houston.

Many travelers know about the B2C flight-tracking functionality of FlightAware. "That's a very, very competitive space. We play in that space, but it's not our core business," founder and CEO Daniel Baker says.

These days, the privately held Houston company earns most its revenue from the B2B data it provides to airlines and other aviation clients, according to Baker. He declines to reveal revenue figures, but notes that the company — which bills itself as the world's largest flight-tracking and flight data platform — hasn't taken a penny of outside funding since it started in 2005.

Today, FlightAware employs about 110 people, with the majority of them located in Houston, Baker says. The company also maintains offices in Austin, New York City, London, and Singapore.

By the end of 2020, the companywide workforce should exceed 135, as FlightAware aims to add three new hires per month this year in areas such as Internet of Things, data science, sales, and administration, Baker says. Most of the new employees will work in Houston.

Baker says FlightAware takes an aggressive approach to hiring, with the goal of bringing aboard "really awesome people" who share levels of talent, collaboration, and "culture fit" similar to those of current employees.

By the end of 2021, FlightAware likely will run out of room in its 24,000-square-foot office at 11 Greenway Plaza in the Greenway/Upper Kirby area, Baker says. That means FlightAware will need to take about 15,000 additional square feet at 11 Greenway Plaza or relocate to a different building, he says. The company moved into its current home in 2017 from a 14,000-square-foot office at 8 Greenway Plaza.

Baker, who's a private pilot and a board member of the Smithsonian Institution's National Air and Space Museum, launched the company 15 years ago as a way to combine two passions: software development and aviation.

"It was originally a hobby, and it became a business," Baker says. "It's an unlikely story. We're really, really fortunate that the timing was right."

Although FlightAware started off tracking flights in the general aviation space, it has since expanded to supply aviation data to both travelers and businesses. Each month, about 15 million passengers use the FlightAware app, which earns praise from a slew of travel critics.

Among flight-tracking apps, FlightAware "is a bit of a Swiss army knife," Condé Nast Traveler magazine observes. The FlightAware app lets you follow flights in real time, including where an incoming plane is coming from, how close it is to arriving, and what kind of weather it's encountering en route, the magazine notes. In addition, the app can send push notifications about arrivals, departures, gate changes, flight delays, and flight cancellations.

Now, FlightAware relies on the consumer-facing technology "as a stepping stone to have a bigger impact," Baker says. "Every project that we undertake is larger than the last one."

That "bigger impact" involves cranking out data that enables commercial airlines, cargo carriers, business aviation companies, and air traffic controllers to be proactive instead of reactive regarding flight activity, he says.

FlightAware's corporate customers include United Airlines, Hawaiian Airlines, business-jet operator NetJets and GPS technology provider Garmin. Baker says a North American airline that he declines to name will soon roll out FlightAware technology to its airport gate agents.

For airlines, FlightAware's software delivers data to cut down, among other issues, on problems with flight delays, gate assignments, and flight connections, Baker says. FlightAware pulls data from its network of more than 25,000 receivers on all seven continents.

While the consumer-oriented features of FlightAware's technology face competition from the likes of FlightStats, FlightView, and The Flight Tracker, the B2B landscape is less populated. Over the years, corporate giants like Airbus, Boeing, and IBM have tackled aviation data on their own but have wound up forging data partnerships with FlightAware, according to Baker.

"We see every potential competitor as a future customer," Baker says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”